SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is currently driving intense community discussion and high volatility as investors weigh the stock's massive long-term potential in AI infrastructure against macro-driven price swings. Sentiment remains sharply divided between bulls confident in the company's hyperscaler partnerships and fundamental growth, and those closely monitoring short interest and potential geopolitical risks affecting the broader tech sector.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as investors digest an $8.5 billion financing deal aimed at scaling AI infrastructure, despite broader market volatility and selling pressure from high-profile insiders. The community is actively debating the company's heavy debt load and long-term viability against its massive contracted backlog and hyperscaler partnerships.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending as investors navigate a significant supply chain warning regarding capacity bottlenecks at TSMC, which could impact the scaling of AI hardware. Despite this, sentiment remains anchored by the company's strong strategic positioning in custom silicon and its recent massive defense-sector contract, creating a tug-of-war between supply-side constraints and long-term institutional demand.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor confidence driven by a strategic buyback of its stake in Ireland's Fab 34 and analyst upgrades, signaling a potential turnaround in manufacturing capacity and competitive foundry positioning. The community is actively debating the stock's long-term potential as a cornerstone of US semiconductor infrastructure, with bulls focusing on upcoming partnership announcements while keeping a close watch on broader geopolitical tensions.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing intense speculative trading activity as investors react to volatile geopolitical headlines and shifting sentiment around the AI infrastructure cycle. The stock has become a focal point for active debate, with the community split between those anticipating a tactical short squeeze driven by retail buying and those concerned that macroeconomic instability will trigger a broader pullback.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is facing a significant market revaluation as institutional investors rotate capital amid concerns over the timeline for Agentic AI revenue realization. While the community remains split between those scaling into the pullback and others rotating into more immediate AI infrastructure winners, the stock remains a central point of debate regarding the transition from traditional IP licensing to long-term silicon-based AI architecture.

Applied Digital Corporation

Applied Digital is trending as investors position themselves ahead of the upcoming earnings release and anticipate potential announcements regarding a major hyperscaler deal. While geopolitical tensions in the Middle East have introduced volatility, the community remains intensely focused on the company's infrastructure growth, site construction progress, and the potential for a significant short squeeze.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant selling pressure and heightened volatility as investors weigh aggressive share dilution against the company's potential to scale as an AI infrastructure platform. The community remains deeply divided, with bulls pointing to the company's massive power pipeline and upcoming capacity energization, while bears highlight concerns over capital expenditures, lack of near-term deal flow, and broad market macro instability.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as shares face downward pressure following a landmark court verdict that held the company liable for platform design features contributing to social media addiction, compounded by broader market sensitivity to geopolitical tensions. Investors are also actively analyzing the impact of Google's new TurboQuant technology on semiconductor demand and navigating ongoing news regarding the company's strategic infrastructure investments and partnerships.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as community members rally behind the iconic, original internet meme culture, emphasizing a long-term 'bagworking' strategy and the utility of their restored meme-creation platform. Supporters are actively promoting the token as an inevitable, undervalued asset within the broader Solana meme ecosystem, driven by high-conviction narratives of long-term growth and community-led development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

<ul class="summary-bullets"><li>The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.</li><li>The proposal includes amending the ongoing VERSATILE-003 Phase 3 study to add progression-free survival as an earlier primary endpoint, potentially allowing for an earlier submission.</li><li>Retail traders on Stocktwits flooded discussions with optimism, calling the stock “too cheap” and speculating that the FDA could grant early approval to give patients faster access to the therapy.</li></ul>Shares of PDS Biotechnology logged their best session in more than two months after the late-stage immunotherapy company said it has requested a meeting with the U.S. Food and Drug Administration to discuss an expedited approval pathway for PDS0101, its lead candidate in HPV16-positive head and neck cancer.<h2 class="st-heading-2">FDA Meeting Request</h2>The company said the request follows a review of the final VERSATILE-002 trial data and a proposal to amend the ongoing VERSATILE-003 Phase 3 study. The amendment would reduce the number of patients while maintaining statistical power and add progression-free survival (PFS) as an earlier primary endpoint, alongside median overall survival (mOS).If the PFS endpoint is met, it could allow for an accelerated approval submission to the FDA. While the amendment is under review, the VERSATILE-003 trial will be temporarily paused, though treatment for currently enrolled patients will continue.<h2 class="st-heading-2">Almost 40 Months Of Median Survival</h2>CEO Frank Bedu-Addo said the final survival results from VERSATILE-002 were “very exciting,” noting that it was the first trial in the recurrent or metastatic head and neck cancer population to show a median overall survival of almost 40 months. He added that seeking to include PFS as an earlier primary endpoint could shorten the trial duration.Chief Medical Officer Kirk Shepard said the company’s goal is to pursue the fastest and most cost-effective regulatory path for approval and to provide a non-chemotherapy option for patients who currently lack effective therapies.<h2 class="st-heading-2">Trial Background</h2>VERSATILE-002 is an open-label, multi-center Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for unresectable, recurrent or metastatic HPV16-positive head and neck cancer.On Stocktwits, retail sentiment for PDS Biotechnology was ‘extremely bullish’ amid a 2,333% surge in 24-hour message volume.<h2 class="st-heading-2">Stocktwits Bulls Bet On Early FDA Nod</h2>One user said the news was “very good” and that the stock looked “way too cheap,” suggesting they were watching for more upside.<stembedurl>https://stocktwits.com/makedatbread88/message/634249334</stembedurl>Another user speculated that the FDA might allow an early approval if PDS agreed to continue trials at the same time, calling it a move that could give very sick head and neck cancer patients access to a potentially life-saving therapy.<stembedurl>https://stocktwits.com/Stockman824/message/634214470</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDS Biotechnology’s stock</a> has declined 38% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

PDS Biotechnology’s stock (PDSB) has declined 38% so far in 2025. | Image source: Getty Images

PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval

The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.

Equity

<ul class="summary-bullets"><li>Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.</li><li>Non-GAAP earnings rose to $2.61 per share, with operating margins improving despite restructuring and impairment charges.</li><li>Retail traders on Stocktwits turned bullish, setting upside targets between $170 and $200 for the stock.</li></ul>Shares of Align Technology rose about 16% in after-hours trading on Wednesday after the Invisalign maker reported third-quarter (Q3) revenue above its own forecast and showed improving momentum in clear aligners for teens and kids.<h2 class="st-heading-2">Results Beat Company Outlook</h2>Align reported Q3 revenue of $995.7 million, up 1.8% year over year and above its guidance range of $965 million to $985 million, though down 1.7% from the prior quarter as the company had flagged. Currency helped, adding about $15.6 million year on year.Clear Aligner revenue was $805.8 million, up 2.4% from a year earlier and flat sequentially. Total clear aligner volume rose 4.9% to 647,800 cases, with the biggest tailwind from younger patients.Treatments for teens and kids jumped 8.3% year over year and 14.7% from Q2 to 256,000 cases, helped by more doctors submitting cases and continued adoption of Invisalign First.The Imaging Systems and CAD/CAM business, which includes iTero scanners, brought in $189.9 million, down 0.6% year over year and 8.6% sequentially, which the company said was normal Q3 capital-equipment seasonality.<h2 class="st-heading-2">Profitability&nbsp;</h2>GAAP operating income was $96.3 million for an operating margin of 9.7%, lower than last year, mainly because the quarter included $88.3 million of restructuring, impairment and accelerated depreciation charges. On a non-GAAP basis, operating margin improved to 23.9%.Net income fell to $56.8 million, or $0.78 per share, from $1.55 a year earlier, largely because of those one-time charges. Non-GAAP EPS was $2.61, up from $2.35.Align ended the quarter with $1 billion in cash and cash equivalents, up from $901 million in the second quarter (Q2).<h2 class="st-heading-2">Outlook</h2>For the fourth quarter (Q4), Align expects revenue of $1.025 billion to $1.045 billion, with clear aligner volume, ASP and systems revenue all seen improving sequentially, and non-GAAP operating margin around 26%.&nbsp;For full-year 2025, the company still expects clear aligner volume to grow in the mid-single digits and revenue to be flat to slightly higher than 2024, reflecting a mixed dental market, especially in North America.<h2 class="st-heading-2">Stocktwits Users Cheer Align’s Strong Quarter</h2>On Stocktwits, retail sentiment for Align was ‘bullish’ amid ‘extremely high’ message volume.One user said Align remains the clear market leader after the quarter and that they were bullish on the stock getting back above $170 by year-end, with a price target of $200 by the first quarter of 2026.&nbsp;<stembedurl>https://stocktwits.com/durocali/message/634224575</stembedurl>Another user said the print was a big beat and flagged $155 as the level to watch on the upside, noting there were still higher gaps to be filled.<stembedurl>https://stocktwits.com/SpudZone/message/634224376</stembedurl><a href="https://stocktwits.com/symbol/ALGN">Align’s stock</a> has declined 37% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Align Technology logo is displayed on a smartphone with a S&P index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)

Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026

Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.

Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/980-iotecheportsullear2024inancialesultsandr20250327">reported</a> better-than-feared losses for 2024.PDS Biotechnology reported a loss per share of $1.03 for the year, narrower than the $1.39 reported for 2023 and better than an analyst estimate of $1.11, according to FinChat data.Net loss narrowed to $37.61 million in 2024 compared to $42.94 million in the prior year.The reduced losses, the company said, were primarily due to a decrease in operating expenses.Research and development expenses fell during the year to $22.6 million from $27.8 million a year ago, owing to reduced clinical costs, personnel costs, and professional fees.The company ended the year with a cash balance of $41.7 million.Last month, PDS Biotechnology announced an up to $22 million registered direct offering. The company said the securities purchase agreements with new and existing healthcare-focused institutional investors included $11 million of upfront gross proceeds.It also included up to an additional $11 million of aggregate gross proceeds upon cash exercise in full of warrants issued to the investors.PDS is a late-stage immunotherapy company developing investigational products designed to stimulate and enhance targeted T cell responses against cancers.Earlier this month, the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to evaluate a combination of its investigational immunotherapy candidate Versamune MUC1 with a novel investigational tumor-targeting Interleukin 12 to treat colorectal carcinoma in certain patients who failed previous treatment.On Stocktwits, the retail investor sentiment about PDS Biotechnology dropped further into the ‘bearish’ territory (32/100), while message volume remained at the ‘extremely low’ level over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_12_26_56_PM_png_6c503f4d3f.webp" alt="PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>PDSB's Sentiment Meter and Message Volume as of 12:27 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure>After the company released its earnings report, HC Wainwright analyst Joseph Pantginis lowered the firm’s price target to $13 from $21 while keeping a ‘Buy’ rating on the shares.A Stocktwits user, however, expressed optimism on the company.<stembedurl>https://stocktwits.com/AyR15/message/609402462</stembedurl>Another user opined that the results were “not as bad as predicted.”<stembedurl>https://stocktwits.com/Mr_Charlie/message/609407057</stembedurl><a href="https://stocktwits.com/symbol/PDSB">PDSB shares</a> have lost over 25% this year and over 65% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/toncoin-gains-outpace-bitcoin-ethereum-after-musk-grok-ai-goes-beyond-x-to-telegram/chJ2BLTRbEJ">Toncoin Gains Outpace Bitcoin, Ethereum After Musk’s Grok AI Goes Beyond X To Telegram – Retail’s Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish

The company said the reduced losses were primarily due to decreased operating expenses.  

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

PDSB
PDS Biotechnology Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PDSB News

PDSBPDS Biotechnology Corporation